|
We asked 40 pharma leaders, do you think the growing number of anticounterfeiting technologies, coupled with increased focus from regulators, have had a positive impact on reducing the number of counterfeit pharmaceuticals in the legal supply chain?
| Yes |
50% |
| No |
16% |
| Technologies have but regulations are still inadequate |
26% |
| Regulations have but technologies are still inadequate |
8% |
 |
|
|
|
|
|
|
|
23 October, 2012
|
| In this Issue |
|
Ethics in Drug Innovation: A Matter of Trust
Ethics is a matter of trust, which in the regulatory space requires transparency and openness among all stakeholders, including patients and industry. This was the consensus of FDA Commissioner Margaret Hamburg and European Medicines Agency (EMA) Executive Director Guido Rasi, both of whom shared the at a plenary lunch panel on “Ethics of Innovation” last week. Read more... |
Whistleblower Case Highlights FDA Security Concerns
The news stories earlier this year that FDA scientists have been suspected of leaking secret information to the media highlight grave confidentiality issues for the Agency, writes David L. Rosen. More... |
EMA Focuses on International Collaboration
Nathan Jessop outlines the EMA’s growing emphasis on collaborating with international pharmaceutical regulators in areas such as inspections, safety of medicines and exchange of information on issues of mutual concern. More... |
Read the New Pharm Exec Global Digest
The payer ‘C’ change; Pharm Exec’s Industry Audit; what the new NICE regulations will mean for pharma… It’s all in our October digital issue of the Pharm Exec Global Digest. More...
|
|
|
|
|
